Immunotherapy shows promise for mysterious cancers
NCT ID NCT03752333
First seen Feb 01, 2026 · Last updated Apr 25, 2026 · Updated 8 times
Summary
This study tested the drug pembrolizumab in 35 adults with cancer of unknown primary (CUP), a type of cancer where doctors cannot find where it started. The goal was to see if the drug could shrink tumors and improve survival. Participants received pembrolizumab intravenously, either as their first treatment or after other treatments had failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gastrointestinal Units - The Royal Marsden Hospitals at Sutton and London
Sutton, Surrey, United Kingdom
-
Guy's Cancer Centre
London, United Kingdom
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.